QI
REGN icon

Quotient Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Quotient Investors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,455
Closed -$2.33M – 234
2016
Q1 		$2.33M Buy
6,455
+5,555
+617% +$2.29M 0.85% 35
2015
Q4 		$489K Buy
900
+266
+42% +$144K 0.19% 129
2015
Q3 		$295K Buy
+634
New +$340K 0.07% 159
2014
Q3 		– Sell
-4,400
Closed -$1.24M – 280
2014
Q2 		$1.24M Sell
4,400
-6,985
-61% -$2.07M 0.27% 117
2014
Q1 		$3.42M Sell
11,385
-11,272
-50% -$3.47M 0.78% 39
2013
Q4 		$6.24M Buy
22,657
+100
+0.4% +$28.8K 1.47% 11
2013
Q3 		$7.06M Sell
22,557
-1,347
-6% -$354K 1.84% 2
2013
Q2 		$5.38M Buy
+23,904
New +$5.57M 1.52% 10

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quotient Investors's REGN Position: Q2 2016 in Review

Quotient Investors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2016, closing a stake of 6,455 shares — an estimated $2.33M sold.

Quotient Investors first reported a position in REGN in Q2 2013 and held it in 8 quarters. The position peaked at $7.06M in Q3 2013. 542 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

  • Quotient Investors reported no remaining Regeneron Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Quotient Investors sold 6,455 Regeneron Pharmaceuticals shares in Q2 2016, an estimated $2.33M.
  • Quotient Investors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Quotient Investors's Regeneron Pharmaceuticals position peaked at $7.06M in Q3 2013.
  • 542 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on Quotient Investors's 13F filing for Q2 2016, filed 11 Jul 2016.